A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Capecitabine (Primary) ; Dendritic cell vaccines (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
Most Recent Events
- 25 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2022 New trial record